A retrospective study of 12 BM patients with ALK, EGFR, and ROS1-driven NSCLC described that extensive BM (> 10 BMs or leptomeningeal disease [LMD]) patients might achieve disease downstaging after receiving high CNS-active TKIs. This evidence concerns the gene ALK and non-small cell lung carcinoma.